Pediatric Clinical Trials

Pediatric Sarcoma

If you would like to inquire about all open trials, please contact 919.684.3401.

5 trials identified.

D9902, A COG Soft Tissue Sarcoma Diagnosis Biology and Banking Protocol
Phase: N/A
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Purpose: The purpose of this study is to collect and store tumor tissue, blood, and bone marrow samples from patients with soft tissue sarcoma that will be tested in the laboratory. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients to test in the laboratory may help the study of cancer.
Reference Number: 00004919
View this trial at ClinicalTrials.gov

AEWS1031 A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Purpose: This randomized phase III trial studies combination chemotherapy to see how well it works compared to combination chemotherapy with topotecan hydrochloride in treating patients with non-metastatic extracranial Ewing sarcoma. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, etoposide, and topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective with topotecan hydrochloride in treating Ewing sarcoma.
Reference Number: 00028814
View this trial at ClinicalTrials.gov

ARST1321 Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Purpose: This randomized phase II/III trial studies how well pazopanib hydrochloride, combination chemotherapy, and radiation therapy work and compares it to radiation therapy alone or in combination with pazopanib hydrochloride or combination chemotherapy in treating patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy works better when given with or without combination chemotherapy and/or pazopanib hydrochloride in treating patients with non-rhabdomyosarcoma soft tissue sarcomas.
Reference Number: 00056072
View this trial at ClinicalTrials.gov

AEWS1221 Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Pediatric Oncology Clinical Trials Office
Phone: 919.684.3401
Purpose: This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma.
Reference Number: 00060489
View this trial at ClinicalTrials.gov

AOST1321 Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Susan Kreissman
Contact: Dr. Susan Kreissman
Phone: 919.684.3401
Purpose: This phase II trial studies how well denosumab works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Monoclonal antibodies, such as denosumab, may block tumor growth in different ways by targeting certain cells.
Reference Number: 00070775
View this trial at ClinicalTrials.gov